<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:bbbc3946-fb83-45df-a79a-1eda869d456e,g:3bfc2a65-34c3-48b9-9b7f-a9b12f04db28,d:b777e768faa843509d45e5c7ad3d86d1--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>smmt-20220727</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV80L2ZyYWc6YTQxNTIwZjVkMzM3NDFlMWIzNjQwYTQyMDEyM2NjNDcvdGFibGU6MDg5ZTEyOWUzYjA2NDM2NmJlMGUxMDYyMGU5N2ZiYzgvdGFibGVyYW5nZTowODllMTI5ZTNiMDY0MzY2YmUwZTEwNjIwZTk3ZmJjOF8wLTEtMS0xLTkxNzEx_ab5a28cf-aa7c-49b1-a288-c792f1cec887">0001599298</ix:nonNumeric><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV80L2ZyYWc6YTQxNTIwZjVkMzM3NDFlMWIzNjQwYTQyMDEyM2NjNDcvdGFibGU6MDg5ZTEyOWUzYjA2NDM2NmJlMGUxMDYyMGU5N2ZiYzgvdGFibGVyYW5nZTowODllMTI5ZTNiMDY0MzY2YmUwZTEwNjIwZTk3ZmJjOF8xLTEtMS0xLTkxNzEx_d819f94b-1c26-48e4-9481-ddf0b127b5ea">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="smmt-20220727.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-27</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib777e768faa843509d45e5c7ad3d86d1_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGV4dHJlZ2lvbjo2OTEwYzA3NDQ5Yjg0MjVkYjMxYmMwMGM4OGE4ZTFhZl80OTMx_aa5cec6a-1aaf-43ab-a3a1-48f7e653a9cf">8-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date of Report (Date of Earliest Event Reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGV4dHJlZ2lvbjo2OTEwYzA3NDQ5Yjg0MjVkYjMxYmMwMGM4OGE4ZTFhZl8yMjg_9743d9aa-7100-4d27-9e8b-bc63287dd398">July 27, 2022</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="padding-left:5.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGFibGU6MDExMDBlMjE2OWZlNDM1OWFlYmNkZjA4YmU2MTVhNDAvdGFibGVyYW5nZTowMTEwMGUyMTY5ZmU0MzU5YWViY2RmMDhiZTYxNWE0MF8wLTAtMS0xLTkxNzEx_296657e0-5be4-4b86-9ba7-637d4d85e1b0">Summit Therapeutics Inc.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Its Charter)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGFibGU6MDExMDBlMjE2OWZlNDM1OWFlYmNkZjA4YmU2MTVhNDAvdGFibGVyYW5nZTowMTEwMGUyMTY5ZmU0MzU5YWViY2RmMDhiZTYxNWE0MF8zLTAtMS0xLTkxNzEx_360bcbd1-72ed-4cfa-89b6-4d1be3537b13">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGFibGU6MDExMDBlMjE2OWZlNDM1OWFlYmNkZjA4YmU2MTVhNDAvdGFibGVyYW5nZTowMTEwMGUyMTY5ZmU0MzU5YWViY2RmMDhiZTYxNWE0MF8zLTEtMS0xLTkxNzEx_02353e49-9c7f-4b22-b69e-4967b8ca172c">001-36866</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGFibGU6MDExMDBlMjE2OWZlNDM1OWFlYmNkZjA4YmU2MTVhNDAvdGFibGVyYW5nZTowMTEwMGUyMTY5ZmU0MzU5YWViY2RmMDhiZTYxNWE0MF8zLTItMS0xLTkxNzEx_08d7c9c1-ae47-4001-9249-56cc717d5059">37-1979717</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Commission<br/>File Number)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(IRS Employer<br/>Identification No.)</span></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGFibGU6MDExMDBlMjE2OWZlNDM1OWFlYmNkZjA4YmU2MTVhNDAvdGFibGVyYW5nZTowMTEwMGUyMTY5ZmU0MzU5YWViY2RmMDhiZTYxNWE0MF82LTAtMS0xLTkxNzExL3RleHRyZWdpb246NDVhZWM1OThjN2RiNGY3NmI3MzExMTFhNTk5NDdmZTZfNQ_0240b388-16d2-4132-b157-e031923c9688">2882 Sand Hill Road, Suite 106</ix:nonNumeric>, <ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGFibGU6MDExMDBlMjE2OWZlNDM1OWFlYmNkZjA4YmU2MTVhNDAvdGFibGVyYW5nZTowMTEwMGUyMTY5ZmU0MzU5YWViY2RmMDhiZTYxNWE0MF82LTAtMS0xLTkxNzExL3RleHRyZWdpb246NDVhZWM1OThjN2RiNGY3NmI3MzExMTFhNTk5NDdmZTZfOQ_deaed1b6-225f-435e-8460-9d694ef8a7a0">Menlo Park</ix:nonNumeric>, <ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGFibGU6MDExMDBlMjE2OWZlNDM1OWFlYmNkZjA4YmU2MTVhNDAvdGFibGVyYW5nZTowMTEwMGUyMTY5ZmU0MzU5YWViY2RmMDhiZTYxNWE0MF82LTAtMS0xLTkxNzExL3RleHRyZWdpb246NDVhZWM1OThjN2RiNGY3NmI3MzExMTFhNTk5NDdmZTZfMTM_e54e761a-fbbe-457f-a5a7-a6f47fae1e1f">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGFibGU6MDExMDBlMjE2OWZlNDM1OWFlYmNkZjA4YmU2MTVhNDAvdGFibGVyYW5nZTowMTEwMGUyMTY5ZmU0MzU5YWViY2RmMDhiZTYxNWE0MF82LTItMS0xLTkxNzEx_6a040d5e-d896-4a55-bbb7-bdca7e742701">94025</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Zip Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Registrant&#8217;s Telephone Number, Including Area Code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGV4dHJlZ2lvbjo2OTEwYzA3NDQ5Yjg0MjVkYjMxYmMwMGM4OGE4ZTFhZl8yODk_e8c7fc1f-dced-417b-b737-be91e0454137">617</ix:nonNumeric>-<ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGV4dHJlZ2lvbjo2OTEwYzA3NDQ5Yjg0MjVkYjMxYmMwMGM4OGE4ZTFhZl80OTI2_21c927e2-bede-4c20-967b-0ffed34a34ff">514-7149</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="padding-left:5.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Former Name or Former Address, If Changed Since Last Report)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGV4dHJlZ2lvbjo2OTEwYzA3NDQ5Yjg0MjVkYjMxYmMwMGM4OGE4ZTFhZl80OTI4_64c64ff3-55c8-4c96-90b7-2fa8dd04cba9">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGV4dHJlZ2lvbjo2OTEwYzA3NDQ5Yjg0MjVkYjMxYmMwMGM4OGE4ZTFhZl80OTI0_dfb18ec3-2b51-4b45-9fe5-9530643255e4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGV4dHJlZ2lvbjo2OTEwYzA3NDQ5Yjg0MjVkYjMxYmMwMGM4OGE4ZTFhZl80OTMy_efe327a1-02d1-403d-8bdc-b045b97431ee">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGV4dHJlZ2lvbjo2OTEwYzA3NDQ5Yjg0MjVkYjMxYmMwMGM4OGE4ZTFhZl80OTI5_88395213-d00f-47e0-9e8e-a76e33f5990f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:6.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title of Each Class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGFibGU6MzU5NWViNzVhZTAyNDlkZWEzZWY1OGY4OTAwMGI3MGIvdGFibGVyYW5nZTozNTk1ZWI3NWFlMDI0OWRlYTNlZjU4Zjg5MDAwYjcwYl8xLTAtMS0xLTkxNzEx_6af02e74-895e-4eb2-bc5c-7a1b1e5aa809">Common stock, $0.01&#160;par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGFibGU6MzU5NWViNzVhZTAyNDlkZWEzZWY1OGY4OTAwMGI3MGIvdGFibGVyYW5nZTozNTk1ZWI3NWFlMDI0OWRlYTNlZjU4Zjg5MDAwYjcwYl8xLTEtMS0xLTkxNzEx_4fc04a23-9dbb-4f33-a386-04da4e578d54">SMMT</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGFibGU6MzU5NWViNzVhZTAyNDlkZWEzZWY1OGY4OTAwMGI3MGIvdGFibGVyYW5nZTozNTk1ZWI3NWFlMDI0OWRlYTNlZjU4Zjg5MDAwYjcwYl8xLTItMS0xLTkxNzEx_c922b48a-41c9-4d1f-8530-ca4404ae3e63">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ia0af3e9a865948fb87b9cf618f9086dd_D20220727-20220727" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmI3NzdlNzY4ZmFhODQzNTA5ZDQ1ZTVjN2FkM2Q4NmQxL3NlYzpiNzc3ZTc2OGZhYTg0MzUwOWQ0NWU1YzdhZDNkODZkMV8xL2ZyYWc6NjkxMGMwNzQ0OWI4NDI1ZGIzMWJjMDBjODhhOGUxYWYvdGV4dHJlZ2lvbjo2OTEwYzA3NDQ5Yjg0MjVkYjMxYmMwMGM4OGE4ZTFhZl80OTMw_92ab1e54-7adc-4702-8217-b4f20f56f94d">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:14.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 5.07</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Submission of Matters to a Vote of Security Holders.</span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On July 27, 2022, Summit Therapeutics Inc. (the &#8220;Company&#8221;) held a Special Meeting of Stockholders (the &#8220;Special Meeting&#8221;). The following matters were submitted to a vote of the Company&#8217;s stockholders at the Special Meeting: (i) an amendment to the Company&#8217;s Restated Certificate of Incorporation, dated September 18, 2020, to increase the number of authorized shares of common stock by 100,000,000 (from 250,000,000 to 350,000,000); and (ii) an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the &#8220;Plan&#8221;) to increase the number of shares of the Company&#8217;s common stock issuable under the Plan by 8,000,000 shares.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Each of the matters submitted to a vote of the Company&#8217;s stockholders at the Special Meeting was approved by the requisite vote of the Company&#8217;s stockholders in accordance with the recommendation of the Company&#8217;s Board of Directors. Set forth below is the number of votes cast for, against or withheld as to each such matter:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Proposal 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">For</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Against</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Abstain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Broker</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amendment to Restated Certificate of Incorporation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">84,235,421</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">184,078</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7,668</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Proposal 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">For</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Against</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Abstain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Broker</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amendment to Summit Therapeutics Inc. 2020 Stock Incentive Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">77,967,560</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,453,957</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,650</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8239; </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.743%"><tr><td style="width:1.0%"></td><td style="width:22.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other Events.</span></div></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In connection with the Special Meeting, the results of which are discussed in Section 5.07 above, the Company filed an Amendment to its Restated Certificate of Incorporation (the &#8220;Amendment&#8221;) to increase the number of authorized shares of common stock by 100,000,000 (from 250,000,000 to 350,000,000). The form of the Amendment is attached hereto as Exhibit 3.1. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.743%"><tr><td style="width:1.0%"></td><td style="width:22.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statements and Exhibits.</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) Exhibits</span></div><div><span><br/></span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3pt;padding-right:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Exhibit Number</span></div></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.02pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="summittherapeuticsinc-de.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="summittherapeuticsinc-de.htm">Amendment to Restated Certificate of Incorporation of Summit Therapeutics Inc., dated July 27, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</span></div><div style="padding-left:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SUMMIT THERAPEUTICS&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: July 29, 2022</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Ankur Dhingra</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "smmt-20220727.htm", "description": "8-K", "secsgml_size_bytes": 46779}]
{"company-data": {"conformed-name": "Summit Therapeutics Inc.", "cik": "0001599298", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36866", "film-number": "221118864"}, "business-address": {"street1": "2882 SAND HILL ROAD", "street2": "SUITE 106", "city": "MENLO PARK", "state": "CA", "zip": "94025", "phone": "617-514-7149"}, "mail-address": {"street1": "2882 SAND HILL ROAD", "street2": "SUITE 106", "city": "MENLO PARK", "state": "CA", "zip": "94025"}, "former-company": [{"former-conformed-name": "Summit Therapeutics plc", "date-changed": "20150219"}, {"former-conformed-name": "Summit Corp plc", "date-changed": "20140205"}]}
smmt-20220727
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
July 27, 2022
Summit Therapeutics Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
001-36866
37-1979717
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
2882 Sand Hill Road, Suite 106
,
Menlo Park
,
CA
94025
(Address of Principal Executive Offices)
(Zip Code)
Registrant's Telephone Number, Including Area Code:
617
-
514-7149
Not applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.01 par value per share
SMMT
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.07
Submission of Matters to a Vote of Security Holders.
On July 27, 2022, Summit Therapeutics Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting"). The following matters were submitted to a vote of the Company's stockholders at the Special Meeting: (i) an amendment to the Company's Restated Certificate of Incorporation, dated September 18, 2020, to increase the number of authorized shares of common stock by 100,000,000 (from 250,000,000 to 350,000,000); and (ii) an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the "Plan") to increase the number of shares of the Company's common stock issuable under the Plan by 8,000,000 shares.
Each of the matters submitted to a vote of the Company's stockholders at the Special Meeting was approved by the requisite vote of the Company's stockholders in accordance with the recommendation of the Company's Board of Directors. Set forth below is the number of votes cast for, against or withheld as to each such matter:
Proposal 1
For
Against
Abstain
Broker
Amendment to Restated Certificate of Incorporation
84,235,421
184,078
7,668
—
Proposal 2
For
Against
Abstain
Broker
Amendment to Summit Therapeutics Inc. 2020 Stock Incentive Plan
77,967,560
6,453,957
5,650
—
Item 8.01
Other Events.
In connection with the Special Meeting, the results of which are discussed in Section 5.07 above, the Company filed an Amendment to its Restated Certificate of Incorporation (the "Amendment") to increase the number of authorized shares of common stock by 100,000,000 (from 250,000,000 to 350,000,000). The form of the Amendment is attached hereto as Exhibit 3.1.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
Description
3.1
Amendment to Restated Certificate of Incorporation of Summit Therapeutics Inc., dated July 27, 2022
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
SUMMIT THERAPEUTICS INC.
Date: July 29, 2022
By:
/s/ Ankur Dhingra
Chief Financial Officer